Skip to main content
Premium Trial:

Request an Annual Quote

BGI Dx, Bioscience Genomics Ink NIPT Deal

NEW YORK (GenomeWeb) – BGI Dx, a subsidiary of BGI, and Italian firm Bioscience Genomics today announced they have signed a five-year framework agreement focused on non-invasive prenatal testing.

The agreement defines terms for the collaboration between the parties, as well as activities and exchanges, and specifically facilitates a technology transfer process for Bioscience Genomics' use of BGI's genetic sequencing technology platforms in the NIPT space.

The technology transfer will allow Bioscience Genomics to start offering NIPT services based on BGI's Nifty test. The test will be called the G-Test in Italy.

The cost related to the transfer of the technology, including setting up a laboratory, is €4.56 million ($5.81 million) with a total anticipated investment of €5.76 million.

Bioscience Genomics is a Rome-based spinout of Bioscience Institute in San Marino, Italy and Tor Vergata University in Rome. The firm offers prenatal diagnostics, newborn screening, and blood and cell banking services